imigran การใช้

• Imigran, also called Imitrex, posted a 29 percent sales rise to 366 million pounds.
• For four years, Imigran was approved in the U . S . only in injectable form.
• Zeneca said that its drug, Zomig, appears to be as strong and effective as Imigran.
• Imitrex, also known as Imigran, is approved in both oral and injectable form in dozens of countries.
• The new drug is expected to compete directly with Glaxo's Imigran, a major Glaxo growth product.
• Glaxo also sells a successor to Imigran called Naramig in Europe, with U . S . approval expected soon.
• "The downside of these results is disappointment over Imigran, " said Nigel Barnes, analyst with Merrill Lynch.
• Also posting strong gains was Imigran, also known as Imitrex, a new migraine treatment in a market with few effective treatments.
• Of the newer products, Imigran, also called Imitrex, posted sales growth of more than 60 percent in the first half.
• New York-based Pfizer, for instance, said recently that its treatment, eletriptan, seemed to work faster than Imigran.
• Many analysts say it is unlikely new products such as Imigran and Epivir will be able fill any gap left by Zantac and Zovirax.
• _The migraine drug Imigran, which grew by 46 percent for sales that came to 500 million pounds ( dlrs 780 million ).
• Imigran generated a 27 percent rise in sales to 310 million pounds, after generating a 46 percent rise in the full year of 1996.
• Greig Middleton estimates that Imigran could generate sales of 650 million pounds at peak sales, which usually takes three to eight years after major market approvals.
• Products introducted since 1990 grew by 50 percent to 2 billion pounds, including Imigran, the anti-asthma treatment Serevent, and the AIDS drug Epivir.
• Glaxo Wellcome's migraine drugs, Imigran-Imitrex and Naramig-Amerge, enjoyed 13 percent sales growth in the huge U . S . market.
• Coombe said Imigran could be getting close to saturating the market, although new migraine treatments being introduced in coming years are likely to grow the headache treatment market.
• Coombe said Imigran could be getting close to saturating the market, although new migraine treatments being introduced in coming years are likely to expand the headache treatment market.
• Vanguard Medica, a small U . K . biotechnology company, said the treatment it is developing with SmithKline Beecham has none of Imigran's worrisome cardiac effects.
• Sales of products introduced since 1990 grew by 50 percent to 2 billion pounds, including Imigran, the anti-asthma treatment Serevent, and the AIDS drug Epivir.